Cannabigerolic acid showed anticonvulsant effects in Dravet syndrome mice but had proconvulsant effects at high doses in another seizure model
CBGA, a precursor cannabinoid, reduced seizures in Dravet syndrome mice and potentiated clobazam, but showed proconvulsant effects in a different seizure model and at high doses.
Quick Facts
What This Study Found
Screening identified CBGA, CBDVA, and CBGVA as novel anticonvulsants. CBGA was most potent and potentiated clobazam against both heat-induced and spontaneous seizures in Scn1a+/- (Dravet) mice. However, CBGA was proconvulsant in the 6-Hz threshold test and a high dose increased spontaneous seizure frequency. CBGA interacted with GPR55, TRPV1, and GABA-A receptors.
Key Numbers
CBGA, CBDVA, and CBGVA identified as anticonvulsant. CBGA potentiated clobazam in Dravet model. CBGA proconvulsant in 6-Hz test. High-dose CBGA increased spontaneous seizure frequency. CBGA interacted with GPR55, TRPV1, GABA-A receptors.
How They Did This
Scn1a+/- mouse model of Dravet syndrome tested against hyperthermia-induced and spontaneous seizures. MES and 6-Hz threshold models also used. Pharmacological profiling across multiple epilepsy-relevant targets (GPR55, TRPV1, GABA-A receptors).
Why This Research Matters
Artisanal cannabis products for childhood epilepsy often contain phytocannabinoids beyond CBD. Identifying which compounds help and which may actually worsen certain seizure types is critical for safe product development.
The Bigger Picture
The dual anticonvulsant/proconvulsant profile of CBGA depending on the seizure type and dose is a cautionary finding for the development of cannabis-based epilepsy treatments beyond CBD.
What This Study Doesn't Tell Us
Mouse models may not predict human responses. The proconvulsant effects at higher doses raise safety concerns. Only one genetic model of epilepsy (Scn1a+/-) was tested. Drug interactions with clobazam could be pharmacokinetic rather than pharmacodynamic.
Questions This Raises
- ?Can the therapeutic window of CBGA be defined to avoid proconvulsant effects?
- ?Would CBGA be safer in combination with other cannabinoids?
- ?Do the multi-target interactions of CBGA create unpredictable effects across seizure types?
Trust & Context
- Key Stat:
- CBGA: anticonvulsant in Dravet model, proconvulsant in 6-Hz model
- Evidence Grade:
- Thorough preclinical characterization across multiple seizure models, but the dual effect profile complicates translation.
- Study Age:
- 2021 animal study. Important safety finding for cannabis products used in childhood epilepsy.
- Original Title:
- Cannabigerolic acid, a major biosynthetic precursor molecule in cannabis, exhibits divergent effects on seizures in mouse models of epilepsy.
- Published In:
- British journal of pharmacology, 178(24), 4826-4841 (2021)
- Authors:
- Anderson, Lyndsey L(10), Heblinski, Marika, Absalom, Nathan L(2), Hawkins, Nicole A, Bowen, Michael T, Benson, Melissa J, Zhang, Fan, Bahceci, Dilara, Doohan, Peter T, Chebib, Mary, McGregor, Iain S, Kearney, Jennifer A, Arnold, Jonathon C
- Database ID:
- RTHC-02968
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
What is CBGA?
Cannabigerolic acid (CBGA) is a precursor molecule in cannabis from which THC, CBD, and other cannabinoids are biosynthesized. It is found in raw cannabis products and some artisanal preparations.
Is CBGA safe for epilepsy?
It showed anticonvulsant effects in a Dravet syndrome model but proconvulsant effects in another seizure model and at high doses. This mixed profile means careful dosing and seizure-type consideration would be essential.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-02968APA
Anderson, Lyndsey L; Heblinski, Marika; Absalom, Nathan L; Hawkins, Nicole A; Bowen, Michael T; Benson, Melissa J; Zhang, Fan; Bahceci, Dilara; Doohan, Peter T; Chebib, Mary; McGregor, Iain S; Kearney, Jennifer A; Arnold, Jonathon C. (2021). Cannabigerolic acid, a major biosynthetic precursor molecule in cannabis, exhibits divergent effects on seizures in mouse models of epilepsy.. British journal of pharmacology, 178(24), 4826-4841. https://doi.org/10.1111/bph.15661
MLA
Anderson, Lyndsey L, et al. "Cannabigerolic acid, a major biosynthetic precursor molecule in cannabis, exhibits divergent effects on seizures in mouse models of epilepsy.." British journal of pharmacology, 2021. https://doi.org/10.1111/bph.15661
RethinkTHC
RethinkTHC Research Database. "Cannabigerolic acid, a major biosynthetic precursor molecule..." RTHC-02968. Retrieved from https://rethinkthc.com/research/anderson-2021-cannabigerolic-acid-a-major
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.